Compare Edwards Lifesciences Corporation Common Stock (EW) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Millicom International Cellular S.A. Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.08 (market cap $49.15B), while Millicom International Cellular S.A. Common Stock trades at $81.05 (market cap $13.34B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 3.7× Millicom International Cellular S.A. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | TIGO | |
|---|---|---|
Market Cap | $49.15B | $13.34B |
Volume | 3,642,969 | 1,586,684 |
Sector | Health | Media |
52-Week High | $95.18 | $104.31 |
52-Week Low | $72.65 | $45.81 |
Enterprise Value | $45.60B | $24.38B |
Typical Hold Time | — | 0 Days |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
